CD52 and T-cell large granular lymphocyte leukemia: Acquired resistance to alemtuzumab therapy in LGLL has been reported to be linked to CD52 down-modulation on LGLL cells [15,46], which eventually re-expresses CD52 upon discontinuation of the drug.